Manning Anthony M. 4

What Happened
Anthony M. Manning, a director of Monte Rosa Therapeutics, was granted a derivative award covering 25,800 shares on June 11, 2026. The Form 4 reports the award at $0.00 (no cash paid at grant). This is a compensation-style grant (award of an option or similar derivative), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-11; Form 4 filed: 2026-06-12 (timely filing).
• Reported as an award/acquisition (code A) of 25,800 shares; price reported = $0.00; classified as a derivative.
• Shares owned after the transaction: not specified in the filing.
• Footnote on vesting: the shares subject to this option vest and become exercisable in full on the earlier of (i) June 11, 2027 or (ii) the issuer's next annual meeting of stockholders, subject to Manning’s continued service.
• No indication of a 10b5-1 plan, cashless exercise, tax-withholding sale, or late filing.

Context
This was a grant of a derivative award (an option-like award) that vests in the future; it is compensation rather than an immediate purchase or sale. Such grants compensate and retain executives/directors and do not by themselves indicate buying or selling sentiment.